Log In
BCIQ
Print this Print this
 

CNP520

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionBetasite APP-cleaving enzyme (BACE) inhibitor
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationAlzheimer's disease (AD)
Indication DetailsPrevent or delay symptoms associated with Alzheimer's disease (AD)
Regulatory Designation
PartnerAmgen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/01/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today